Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.48 |
| ▸ | CDK2 | P24941 | 4/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.48 |
| ▸ | CCND1 | P24385 | 1/20 | 0.48 |
| ▸ | CCND3 | P30281 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.48 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10152493 | 0.80 | GSK3B (0.62) | GSK3BCDK2CCNT1CDK1CDK4 | |
| SCHEMBL3254216 | 0.69 | CDK2 (0.72) | GSK3BCDK2CDK1CDK4CCNB1 | |
| SCHEMBL3602481 | 0.69 | PRKCB (0.40) | GSK3B | |
| SCHEMBL3148363 | 0.66 | MAOA (0.46) | GSK3BCDK2CCNT1CDK1CDK4 | |
| SCHEMBL3603231 | 0.65 | GSK3B (0.43) | GSK3BCDK2CDK1CDK4CCNB1 | |
| SCHEMBL3147853 | 0.65 | DRD4 (0.34) | — | |
| SCHEMBL6538228 | 0.65 | DNA2 (0.47) | GSK3BCDK2CDK5CDK5R1 | |
| SCHEMBL3144378 | 0.65 | GSK3B (1.00) | GSK3BCDK2CCNT1CDK1CDK4 | |
| SCHEMBL2473646 | 0.65 | SMYD2 (0.34) | — | |
| SCHEMBL3144303 | 0.63 | GSK3B (0.62) | GSK3BCDK2CDK1CDK4CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207216-B2 | Benzofuran-3-yl(indol-3-yl) maleimides as potent GSK3 inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207216-B2 | Benzofuran-3-yl(indol-3-yl) maleimides as potent GSK3 inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100004308-A1 | Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, A BODY CORPORATE AND POLITIC OF THE STATE OF ILLINOIS | 2010-01-07 | — | — | US | disclosed |
| US-20100004308-A1 | Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, A BODY CORPORATE AND POLITIC OF THE STATE OF ILLINOIS | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004308-A1 | Benzofuran-3-yl(indol-3-yl) Maleimides as Potent GSK3 Inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885CDK2 610/4885CCNT1 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.